British drugs firm GSK settles US drug disputes for $3.0 bln

GlaxoSmithKline said on Thursday it had agreed to pay $3.0 billion (2.2 billion euros) to settle long-running disputes with the US government over how the British pharmaceuticals group marketed and developed drugs.

GlaxoSmithKline said in a statement that it had "reached an agreement in principle with the US government to conclude the company's most significant ongoing Federal government investigations."

The investigations included the probing of GSK's sales and , begun by the US Attorney's office of Colorado in 2004 and later taken over by the US Attorney's Office of Massachusetts.

And they also referred to the Department of Justice's probe into the development and marketing of its former blockbuster Avandia.

said that it had already set aside sufficient cash funds to pay the legal costs, although some terms still needed to be agreed.

GSK chief executive Andrew Witty said the $3.0 billion deal was "a significant step toward resolving difficult, long-standing matters which do not reflect the company that we are today."

He added in a statement: "In recent years, we have fundamentally changed our procedures for compliance, marketing and selling in the US to ensure that we operate with high standards of integrity and that we conduct our business openly and transparently."

add to favorites email to friend print save as pdf

Related Stories

GSK to take $3.4 bln Avandia legal charge

Jan 17, 2011

British drugs firm GlaxoSmithKline said Monday it expects to take a legal charge of £2.2 billion linked to its former blockbuster diabetes product Avandia, sparking a sharp drop in its shares.

GlaxoSmithKline posts rising Q3 profits

Oct 26, 2011

British drugmaker GlaxoSmithKline said Wednesday that third-quarter net profit rose seven percent, boosted by growth across its main pharmaceuticals, vaccines and consumer healthcare divisions.

Recommended for you

Have a cold? Don't ask your doctor for antibiotics

Nov 26, 2014

Antibiotic resistance is a major threat to public health. Resistance makes it harder for physicians to treat infections and can increase the chance patients will die from an infection. What is more, the treatment ...

Powdered measles vaccine found safe in early clinical trials

Nov 25, 2014

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.